Clinical significance of bromodomain‑containing protein 7 and its association with tumor progression in prostate cancer

Liang,Yong; Dong,Baiping; Shen,Jiangwei; Ma,Caosheng; Ma,Zhongping

doi:10.3892/ol.2018.9665

Clinical significance of bromodomain‑containing protein 7 and its association with tumor progression in prostate cancer

Authors:
- Yong Liang
- Baiping Dong
- Jiangwei Shen
- Caosheng Ma
- Zhongping Ma
View Affiliations

Affiliations: Department of Urology Surgery, Caoxian People's Hospital, Heze, Shandong 274400, P.R. China
Published online on: November 5, 2018 https://doi.org/10.3892/ol.2018.9665
Pages: 849-856
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is a common malignancy in males. The current study assessed the clinical significance of bromodomain‑containing protein 7 (BRD7) and its association with PCa tumor progression. Serum and tissue expression levels of BRD7 were analyzed by reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic value of BRD7. Kaplan‑Meier survival analysis and Cox regression analysis were performed to assess the prognostic performance of BRD7. The association of BRD7 with cell behavior was investigated by transfection with a pcDNA3.1‑BRD7 vector. The results revealed that serum and tissue BRD7 expression levels were significantly decreased in PCa samples compared with normal controls (P<0.001). BRD7 expression was significantly associated with the pathological stage (P=0.037), lymph node metastasis (P=0.009) and TNM stage (P=0.010). An area under the ROC curve of 0.864 was obtained, with a sensitivity and specificity of 77.0 and 83.3%, respectively. Low BRD7 expression was significantly associated with a shorter survival time in both overall survival analysis (P=0.003) and cancer‑specific survival analysis (P=0.029). Furthermore, BRD7 appeared to serve as an independent prognostic factor for PCa. The proliferation, migration and invasion of PCa cells were suppressed by BRD7 overexpression. In summary, downregulation of BRD7 in PCa may be involved in tumor progression and serve as an effective diagnostic and prognostic biomarker.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Feng S, Qian X, Li H and Zhang X: Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer. Oncol Lett. 14:6943–6949. 2017.PubMed/NCBI
3	Matthes KL, Limam M, Dehler S, Korol D and Rohrmann S: Primary treatment choice over time and relative survival of prostate cancer patients: Influence of age, grade, and stage. Oncol Res Treat. 40:484–489. 2017. View Article : Google Scholar : PubMed/NCBI
4	Wu J, Cheng G, Zhang C, Zheng Y, Xu H, Yang H and Hua L: Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis. Onco Targets Ther. 10:1843–1852. 2017. View Article : Google Scholar : PubMed/NCBI
5	Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol. 61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ren SC, Chen R and Sun YH: Prostate cancer research in China. Asian J Androl. 15:350–353. 2013. View Article : Google Scholar : PubMed/NCBI
7	Zhu Y, Yang XQ, Han CT, Dai B, Zhang HL, Shi GH, Wang CF and Ye DW: Pathological features of localized prostate cancer in China: A contemporary analysis of radical prostatectomy specimens. PLoS One. 10:e01210762015. View Article : Google Scholar : PubMed/NCBI
8	Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003. View Article : Google Scholar : PubMed/NCBI
9	Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O and Nakayama J: Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 17:18–22. 2014. View Article : Google Scholar : PubMed/NCBI
10	Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
11	Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW and Dörk T: Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One. 7:e479932012. View Article : Google Scholar : PubMed/NCBI
12	Yoo HM, Kang SH, Kim JY, Lee JE, Seong MW, Lee SW, Ka SH, Sou YS, Komatsu M, Tanaka K, et al: Modification of ASC1 by UFM1 is crucial for ERα transactivation and breast cancer development. Mol Cell. 56:261–274. 2014. View Article : Google Scholar : PubMed/NCBI
13	Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK and Zhou MM: Structure and ligand of a histone acetyltransferase bromodomain. Nature. 399:491–496. 1999. View Article : Google Scholar : PubMed/NCBI
14	Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R and Del Sal G: BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol. 12:380–389. 2010. View Article : Google Scholar : PubMed/NCBI
15	Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, Mullan PB and Harkin DP: BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 70:2538–2547. 2010. View Article : Google Scholar : PubMed/NCBI
16	Mantovani F, Drost J, Voorhoeve PM, Del Sal G and Agami R: Gene regulation and tumor suppression by the bromodomain-containing protein BRD7. Cell Cycle. 9:2777–2781. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yu X, Li Z and Shen J: BRD7: A novel tumor suppressor gene in different cancers. Am J Transl Res. 8:742–748. 2016.PubMed/NCBI
18	Peng C, Liu HY, Zhou M, Zhang LM, Li XL, Shen SR and Li GY: BRD7 suppresses the growth of Nasopharyngeal Carcinoma cells (HNE1) through negatively regulating beta-catenin and ERK pathways. Mol Cell Biochem. 303:141–149. 2007. View Article : Google Scholar : PubMed/NCBI
19	Balasubramanian A, Subramaniam R, Narayanan V, Annamalai T and Ramanathan A: BRD7 promoter hypermethylation as an indicator of well differentiated oral squamous cell carcinomas. Asian Pac J Cancer Prev. 16:1615–1619. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, Imamura M and Hatakeyama S: TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. 1793:1828–1836. 2009. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Parnes HL, House MG and Tangrea JA: Prostate cancer prevention: Agent development strategies. Recent Results Cancer Res. 202:121–131. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW and Li GX: Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer. Oncotarget. 6:41825–41836. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhou L, Xia D, Zhu J, Chen Y, Chen G, Mo R, Zeng Y, Dai Q, He H, Liang Y, et al: Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer. Clin Transl Oncol. 16:906–913. 2014. View Article : Google Scholar : PubMed/NCBI
25	Salinas CA, Tsodikov A, Ishak-Howard M and Cooney KA: Prostate cancer in young men: An important clinical entity. Nat Rev Urol. 11:317–323. 2014. View Article : Google Scholar : PubMed/NCBI
26	Tabayoyong W and Abouassaly R: Prostate cancer screening and the associated controversy. Surg Clin North Am. 95:1023–1039. 2015. View Article : Google Scholar : PubMed/NCBI
27	Xu Y, Cao W, Zhou M, Li C, Luo Y, Wang H, Zhao R, Jiang S, Yang J, Liu Y, et al: Inactivation of BRD7 results in impaired cognitive behavior and reduced synaptic plasticity of the medial prefrontal cortex. Behav Brain Res. 286:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhou M, Liu H, Xu X, Zhou H, Li X, Peng C, Shen S, Xiong W, Ma J, Zeng Z, et al: Identification of nuclear localization signal that governs nuclear import of BRD7 and its essential roles in inhibiting cell cycle progression. J Cell Biochem. 98:920–930. 2006. View Article : Google Scholar : PubMed/NCBI
29	Park YA, Lee JW, Kim HS, Lee YY, Kim TJ, Choi CH, Choi JJ, Jeon HK, Cho YJ, Ryu JY, et al: Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma. Clin Cancer Res. 20:565–575. 2014. View Article : Google Scholar : PubMed/NCBI
30	Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, et al: Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget. 7:16248–16261. 2016.PubMed/NCBI
31	Park YA, Lee JW, Choi JJ, Jeon HK, Cho Y, Choi C, Kim TJ, Lee NW, Kim BG and Bae DS: The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol. 124:125–133. 2012. View Article : Google Scholar : PubMed/NCBI
32	Wu WJ, Hu KS, Chen DL, Zeng ZL, Luo HY, Wang F, Wang DS, Wang ZQ, He F and Xu RH: Prognostic relevance of BRD7 expression in colorectal carcinoma. Eur J Clin Invest. 43:131–140. 2013. View Article : Google Scholar : PubMed/NCBI
33	Hu K, Liao D, Wu W, Han AJ, Shi HJ, Wang F, Wang X, Zhong L, Duan T, Wu Y, et al: Targeting the anaphase-promoting complex/cyclosome (APC/C)-bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget. 5:3088–3100. 2014. View Article : Google Scholar : PubMed/NCBI
34	Gao Y, Wang B and Gao S: BRD7 acts as a tumor suppressor gene in lung adenocarcinoma. PLoS One. 11:e01567012016. View Article : Google Scholar : PubMed/NCBI